NEWTOWN, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a leading class action law firm, is investigating alleged violations of the federal securities laws by officers and directors of Inari Medical, Inc.
Investors who purchased Inari Medical, Inc. stock (NASDAQ:NARI) between February 24, 2022, and February 28, 2024 (the "Class Period") have until July 12, 2024, to move the U.S. District Court for the Southern District of New York to appoint them as lead plaintiff in the pending securities fraud class action lawsuit.
To learn more about this case, please contact Eric Lechtzin of Edelson Lechtzin LLP at 844-696-7492 or by e-mail at elechtzin@edelson-law.com. A copy of the Class Action Complaint can be viewed HERE.
Background on Inari Medical, Inc.
Headquartered in Irvine, California, Inari is a medical device company that focuses on developing, producing, and selling catheter-based technologies. These ...
NARI) Shareholders With Substantial Losses To Consult Counsel About The Pending Securities Fraud Class Action>Full story available on Benzinga.com